Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexa-Vec + Checkpoint Inhibitors in Refractory Colorectal Cancer
NCT03206073Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2017
- Primary completion
- Sep 2020
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus in colorectal cancer (CRC) (4 arms), sponsored by National Cancer Institute. Primary endpoint: Number of Participants With Grade 1-5 Adverse Events. Started Dec 2017; status: completed.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03206073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206073.